Reported Earnings • Aug 11
First quarter 2027 earnings released: EPS: ₹8.46 (vs ₹8.43 in 1Q 2026) First quarter 2027 results: EPS: ₹8.46. Revenue: ₹2.53b (up 21% from 1Q 2026). Net income: ₹176.5m (flat on 1Q 2026). Profit margin: 7.0% (down from 8.4% in 1Q 2026). Announcement • Aug 04
Windlas Biotech Limited to Report Q1, 2027 Results on Aug 10, 2026 Windlas Biotech Limited announced that they will report Q1, 2027 results at 4:00 PM, Indian Standard Time on Aug 10, 2026 Announcement • Jul 25
Windlas Biotech Limited Declares Final Dividend for the Financial Year 2025-26 Windlas Biotech Limited in the AGM meeting held on July 23, 2026, approved declaration of Final Dividend of INR 6.30/- per Equity Share for the financial year 2025-26. Announcement • Jul 24
Windlas Biotech Limited Approves Appointment of Tarashree Singhal as an Independent Director Windlas Biotech Limited in the AGM meeting held on July 23, 2026, approved appointment of Dr. Tarashree Singhal (DIN:11697518) as an Independent Director. Reported Earnings • Jul 04
Full year 2026 earnings released: EPS: ₹31.60 (vs ₹29.19 in FY 2025) Full year 2026 results: EPS: ₹31.60 (up from ₹29.19 in FY 2025). Revenue: ₹9.04b (up 19% from FY 2025). Net income: ₹664.6m (up 9.0% from FY 2025). Profit margin: 7.4% (down from 8.0% in FY 2025). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth. Declared Dividend • Jul 02
Dividend increased to ₹6.30 Dividend of ₹6.30 is 8.6% higher than last year. Ex-date: 16th July 2026 Payment date: 22nd August 2026 Dividend yield will be 0.7%, which is about the same as the industry average. Sustainability & Growth Dividend is well covered by both earnings (20% earnings payout ratio) and cash flows (35% cash payout ratio). The dividend has increased by an average of 16% per year over the past 4 years and payments have been stable during that time. Earnings per share has grown by 30% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Announcement • Jun 30
Windlas Biotech Limited, Annual General Meeting, Jul 23, 2026 Windlas Biotech Limited, Annual General Meeting, Jul 23, 2026, at 13:00 Indian Standard Time. Reported Earnings • May 23
Full year 2026 earnings released: EPS: ₹31.60 (vs ₹29.19 in FY 2025) Full year 2026 results: EPS: ₹31.60 (up from ₹29.19 in FY 2025). Revenue: ₹9.22b (up 21% from FY 2025). Net income: ₹664.6m (up 9.0% from FY 2025). Profit margin: 7.2% (down from 8.0% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 15
Windlas Biotech Limited to Report Q4, 2026 Results on May 21, 2026 Windlas Biotech Limited announced that they will report Q4, 2026 results on May 21, 2026 Announcement • Apr 17
Windlas Biotech Limited (NSEI:WINDLAS) announces an Equity Buyback for 470,000 shares, representing 2.23% for INR 470 million. Windlas Biotech Limited (NSEI:WINDLAS) announces a share repurchase program. Under the program, the company will repurchase up to 470,000 shares, representing 2.23% of its issued share capital, for INR 470 million. The company will repurchase the shares at a price of INR 1,000 per equity share, payable in cash. The buyback is proposed to be made on a proportionate basis. The 15% of the number of equity shares which the company proposes to repurchase or number of equity shares entitled as per the shareholding of small shareholders as on the record date, whichever is higher, shall be reserved for the small shareholders. The record date for the purpose of ascertaining the eligibility of shareholders for the repurchase of shares is April 24, 2026. As of March 31, 2026, the company had 21,106,229 shares outstanding. Reported Earnings • Feb 06
Third quarter 2026 earnings released: EPS: ₹7.12 (vs ₹7.45 in 3Q 2025) Third quarter 2026 results: EPS: ₹7.12 (down from ₹7.45 in 3Q 2025). Revenue: ₹2.38b (up 22% from 3Q 2025). Net income: ₹150.0m (down 3.7% from 3Q 2025). Profit margin: 6.3% (down from 8.0% in 3Q 2025). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jan 28
Windlas Biotech Limited to Report Q3, 2026 Results on Feb 05, 2026 Windlas Biotech Limited announced that they will report Q3, 2026 results on Feb 05, 2026 Reported Earnings • Nov 07
Second quarter 2026 earnings released: EPS: ₹8.48 (vs ₹7.49 in 2Q 2025) Second quarter 2026 results: EPS: ₹8.48 (up from ₹7.49 in 2Q 2025). Revenue: ₹2.26b (up 21% from 2Q 2025). Net income: ₹178.0m (up 14% from 2Q 2025). Profit margin: 7.9% (down from 8.4% in 2Q 2025). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Oct 29
Windlas Biotech Limited to Report Q2, 2026 Results on Nov 06, 2025 Windlas Biotech Limited announced that they will report Q2, 2026 results on Nov 06, 2025 Reported Earnings • Aug 13
First quarter 2026 earnings released: EPS: ₹8.43 (vs ₹6.47 in 1Q 2025) First quarter 2026 results: EPS: ₹8.43 (up from ₹6.47 in 1Q 2025). Revenue: ₹2.15b (up 23% from 1Q 2025). Net income: ₹176.6m (up 31% from 1Q 2025). Profit margin: 8.2% (up from 7.7% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 70% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Aug 09
Windlas Biotech Limited to Report Q1, 2026 Results on Aug 12, 2025 Windlas Biotech Limited announced that they will report Q1, 2026 results on Aug 12, 2025 Announcement • Jul 29
Windlas Biotech Limited Approves Final Dividend for the Financial Year 2024-25 Windlas Biotech Limited announced that at the AGM held on July 28, 2025 approved Final Dividend of INR 5.80/- per Equity Share for the financial year 2024-25. Upcoming Dividend • Jul 14
Upcoming dividend of ₹5.80 per share Eligible shareholders must have bought the stock before 21 July 2025. Payment date: 27 August 2025. Payout ratio is a comfortable 20% and the cash payout ratio is 76%. Trailing yield: 0.6%. Lower than top quartile of Indian dividend payers (1.2%). Higher than average of industry peers (0.4%). Announcement • Jul 06
Windlas Biotech Limited, Annual General Meeting, Jul 28, 2025 Windlas Biotech Limited, Annual General Meeting, Jul 28, 2025, at 13:00 Indian Standard Time. Reported Earnings • May 23
Full year 2025 earnings released: EPS: ₹29.19 (vs ₹27.97 in FY 2024) Full year 2025 results: EPS: ₹29.19 (up from ₹27.97 in FY 2024). Revenue: ₹7.78b (up 23% from FY 2024). Net income: ₹609.9m (up 4.8% from FY 2024). Profit margin: 7.8% (down from 9.2% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 60% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 14
Windlas Biotech Limited to Report Q4, 2025 Results on May 22, 2025 Windlas Biotech Limited announced that they will report Q4, 2025 results on May 22, 2025 Valuation Update With 7 Day Price Move • Apr 15
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹1,070, the stock trades at a trailing P/E ratio of 36.2x. Average trailing P/E is 43x in the Life Sciences industry in India. Total returns to shareholders of 318% over the past three years. Valuation Update With 7 Day Price Move • Feb 26
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₹821, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 48x in the Life Sciences industry in India. Total returns to shareholders of 248% over the past three years. Reported Earnings • Feb 12
Third quarter 2025 earnings released: EPS: ₹7.45 (vs ₹7.26 in 3Q 2024) Third quarter 2025 results: EPS: ₹7.45 (up from ₹7.26 in 3Q 2024). Revenue: ₹1.95b (up 20% from 3Q 2024). Net income: ₹155.8m (up 3.2% from 3Q 2024). Profit margin: 8.0% (down from 9.3% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Feb 11
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹842, the stock trades at a trailing P/E ratio of 28.7x. Average trailing P/E is 52x in the Life Sciences industry in India. Total returns to shareholders of 227% over the past three years. Announcement • Feb 03
Windlas Biotech Limited to Report Q3, 2025 Results on Feb 11, 2025 Windlas Biotech Limited announced that they will report Q3, 2025 results on Feb 11, 2025 Announcement • Jan 10
Windlas Biotech Limited Receives Good Manufacturing Practices Certification for New Injectable Facility from the Food Safety & Drugs Administration Authority of Uttarakhand Windlas Biotech Limited announced that it has received Good Manufacturing Practices (GMP) certification for its new Injectable facility from the Food Safety & Drugs Administration Authority of Uttarakhand, following the inspection in December 2024. The certification states, that the firm is following the Good Manufacturing Practices as per World Health Organization (WHO) TRS Guidelines. Reported Earnings • Nov 13
Second quarter 2025 earnings released: EPS: ₹7.49 (vs ₹6.75 in 2Q 2024) Second quarter 2025 results: EPS: ₹7.49 (up from ₹6.75 in 2Q 2024). Revenue: ₹1.92b (up 26% from 2Q 2024). Net income: ₹156.6m (up 12% from 2Q 2024). Profit margin: 8.2% (down from 9.2% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth. New Risk • Nov 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Announcement • Nov 05
Windlas Biotech Limited to Report Q2, 2025 Results on Nov 12, 2024 Windlas Biotech Limited announced that they will report Q2, 2025 results on Nov 12, 2024 Valuation Update With 7 Day Price Move • Nov 01
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹1,116, the stock trades at a trailing P/E ratio of 39.1x. Average trailing P/E is 48x in the Life Sciences industry in India. Total returns to shareholders of 272% over the past three years. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹998, the stock trades at a trailing P/E ratio of 35x. Average trailing P/E is 51x in the Life Sciences industry in India. Total returns to shareholders of 203% over the past three years. Announcement • Sep 26
Windlas Biotech Limited Approves Final Dividend for the Financial Year 2023-24 Windlas Biotech Limited at its AGM held on September 24, 2024, approved final dividend of INR 5.50 per equity share for the financial year 2023-24. Declared Dividend • Aug 31
Dividend increased to ₹5.50 Dividend of ₹5.50 is 38% higher than last year. Ex-date: 17th September 2024 Payment date: 24th October 2024 Dividend yield will be 0.7%, which is about the same as the industry average. Sustainability & Growth Dividend is well covered by both earnings (19% earnings payout ratio) and cash flows (16% cash payout ratio). The dividend has increased by an average of 25% per year over the past 2 years and payments have been stable during that time. The company's earnings per share (EPS) would need to decline by 79% to shift the payout ratio to a potentially unsustainable range, which is more than the 5.9% EPS decline seen over the last 5 years. Announcement • Aug 30
Windlas Biotech Limited, Annual General Meeting, Sep 24, 2024 Windlas Biotech Limited, Annual General Meeting, Sep 24, 2024, at 14:30 Indian Standard Time. Announcement • Aug 29
Windlas Biotech Limited Proposes Final Dividend for the Financial Year 2023-24 Windlas Biotech Limited at the AGM to be held on September 24, 2024, the shareholders proposed a final dividend of INR 5.50 per equity share for the financial year 2023-24. Reported Earnings • Aug 14
First quarter 2025 earnings released: EPS: ₹6.47 (vs ₹5.79 in 1Q 2024) First quarter 2025 results: EPS: ₹6.47 (up from ₹5.79 in 1Q 2024). Revenue: ₹1.79b (up 24% from 1Q 2024). Net income: ₹134.8m (up 12% from 1Q 2024). Profit margin: 7.5% (down from 8.3% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Aug 02
Windlas Biotech Limited to Report Q1, 2025 Results on Aug 13, 2024 Windlas Biotech Limited announced that they will report Q1, 2025 results on Aug 13, 2024 Valuation Update With 7 Day Price Move • Jul 30
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹798, the stock trades at a trailing P/E ratio of 28.6x. Average trailing P/E is 42x in the Life Sciences industry in India. Total returns to shareholders of 142% over the past year. Reported Earnings • May 21
Full year 2024 earnings released: EPS: ₹27.97 (vs ₹19.70 in FY 2023) Full year 2024 results: EPS: ₹27.97 (up from ₹19.70 in FY 2023). Revenue: ₹6.44b (up 26% from FY 2023). Net income: ₹581.9m (up 37% from FY 2023). Profit margin: 9.0% (up from 8.3% in FY 2023). The increase in margin was driven by higher revenue. Buy Or Sell Opportunity • May 19
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 6.2% to ₹553. The fair value is estimated to be ₹457, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 26%. Announcement • May 12
Windlas Biotech Limited to Report Q4, 2024 Results on May 20, 2024 Windlas Biotech Limited announced that they will report Q4, 2024 results on May 20, 2024 Buy Or Sell Opportunity • Apr 30
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 13% to ₹553. The fair value is estimated to be ₹458, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 26%. Buy Or Sell Opportunity • Apr 22
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 22% to ₹568. The fair value is estimated to be ₹462, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 26%. Buy Or Sell Opportunity • Apr 03
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 11% to ₹559. The fair value is estimated to be ₹460, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 26%. New Risk • Mar 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.1% average weekly change). Buy Or Sell Opportunity • Feb 23
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 28% to ₹547. The fair value is estimated to be ₹456, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 26%. Reported Earnings • Feb 09
Third quarter 2024 earnings released: EPS: ₹7.26 (vs ₹4.23 in 3Q 2023) Third quarter 2024 results: EPS: ₹7.26 (up from ₹4.23 in 3Q 2023). Revenue: ₹1.65b (up 38% from 3Q 2023). Net income: ₹151.0m (up 64% from 3Q 2023). Profit margin: 9.1% (up from 7.7% in 3Q 2023). The increase in margin was driven by higher revenue. Announcement • Jan 31
Windlas Biotech Limited to Report Q3, 2024 Results on Feb 08, 2024 Windlas Biotech Limited announced that they will report Q3, 2024 results on Feb 08, 2024 Valuation Update With 7 Day Price Move • Jan 02
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₹528, the stock trades at a trailing P/E ratio of 23.5x. Average trailing P/E is 22x in the Life Sciences industry in India. Total returns to shareholders of 118% over the past year. Reported Earnings • Nov 14
Second quarter 2024 earnings released: EPS: ₹6.75 (vs ₹5.59 in 2Q 2023) Second quarter 2024 results: EPS: ₹6.75 (up from ₹5.59 in 2Q 2023). Revenue: ₹1.56b (up 18% from 2Q 2023). Net income: ₹140.3m (up 15% from 2Q 2023). Profit margin: 9.0% (down from 9.2% in 2Q 2023). The decrease in margin was driven by higher expenses. Announcement • Oct 31
Windlas Biotech Limited to Report First Half, 2024 Results on Nov 08, 2023 Windlas Biotech Limited announced that they will report first half, 2024 results on Nov 08, 2023 Announcement • Sep 13
Windlas Biotech Limited Approves Final Dividend for the Financial Year 2022-23 Windlas Biotech Limited at the AGM held on September 12, 2023, the shareholders approved a final dividend of INR 4 per equity share for the financial year 2022-23. Upcoming Dividend • Aug 29
Upcoming dividend of ₹4.00 per share at 1.1% yield Eligible shareholders must have bought the stock before 05 September 2023. Payment date: 12 October 2023. Payout ratio is a comfortable 20% but the company is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of Indian dividend payers (1.4%). Higher than average of industry peers (0.6%). Valuation Update With 7 Day Price Move • Aug 15
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹384, the stock trades at a trailing P/E ratio of 17.8x. Average trailing P/E is 24x in the Life Sciences industry in India. Total returns to shareholders of 82% over the past year. Reported Earnings • Aug 09
First quarter 2024 earnings released: EPS: ₹5.79 (vs ₹4.50 in 1Q 2023) First quarter 2024 results: EPS: ₹5.79 (up from ₹4.50 in 1Q 2023). Revenue: ₹1.47b (up 23% from 1Q 2023). Net income: ₹120.7m (up 23% from 1Q 2023). Profit margin: 8.2% (in line with 1Q 2023). Announcement • Aug 01
Windlas Biotech Limited to Report Q1, 2024 Results on Aug 08, 2023 Windlas Biotech Limited announced that they will report Q1, 2024 results on Aug 08, 2023 Reported Earnings • May 06
Full year 2023 earnings released: EPS: ₹19.70 (vs ₹18.58 in FY 2022) Full year 2023 results: EPS: ₹19.70 (up from ₹18.58 in FY 2022). Revenue: ₹5.23b (up 12% from FY 2022). Net income: ₹426.3m (up 12% from FY 2022). Profit margin: 8.1% (down from 8.2% in FY 2022). The decrease in margin was driven by higher expenses. Announcement • May 06
Windlas Biotech Limited Recommends Dividend Windlas Biotech Limited at its board meeting held on May 5, 2023 Recommended a Dividend of INR 4.00/- per Equity Share of face value of INR 5/- each. The said dividend, if declared by the Members of the Company at the ensuing Annual General Meeting (AGM), will be credited/despatched within three weeks of the conclusion of said AGM. Announcement • Feb 10
Windlas Biotech Limited Appoints Komal Gupta as the Chief Executive Officer Windlas Biotech Limited announced that on the recommendation of Nomination and Remuneration Committee, the Board of Directors of the Company at their meeting held on February 08, 2023, approved the appointment of Ms. Komal Gupta as the Chief Executive Officer and Key Managerial Personnel of the Company with effect from February 08, 2023. Ms. Komal Gupta holds a bachelor's degree in commerce from Dr. Babasaheb Ambedkar Marathwada University. She is a fellow member of the Institute of Chartered Accountants of India, an associate member of the Institute of Company Secretaries of India and the Institute of Cost and Works Accountants of India. She has experience in the field of finance. She joined the Company on October 16, 2015. She is currently the Chief Financial Officer of the Company and she will continue as Chief Financial Officer till a suitable person is appointed. Ms. Komal Gupta has an extensive experience in the field of Finance, Accounts, Taxation, Business Finance, Treasury and Compliance. Prior to joining the Company, she has worked with Anand Automotives Group (Perfect Circle India Limited, Mahle Filters Limited, Corporate office Anand Automotive Systems Limited) and DSM Group (DSM Sinochem Pharmaceuticals India Pvt. Ltd., now Centrient Pharmaceuticals India Pvt. Ltd.). Reported Earnings • Feb 09
Third quarter 2023 earnings released: EPS: ₹4.23 (vs ₹3.81 in 3Q 2022) Third quarter 2023 results: EPS: ₹4.23 (up from ₹3.81 in 3Q 2022). Revenue: ₹1.22b (up 3.6% from 3Q 2022). Net income: ₹91.9m (up 11% from 3Q 2022). Profit margin: 7.5% (up from 7.1% in 3Q 2022). The increase in margin was driven by higher revenue. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Non-Executive Independent Director Gaurav Gulati was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 09
Second quarter 2023 earnings released: EPS: ₹5.59 (vs ₹4.11 in 2Q 2022) Second quarter 2023 results: EPS: ₹5.59 (up from ₹4.11 in 2Q 2022). Revenue: ₹1.35b (up 17% from 2Q 2022). Net income: ₹121.9m (up 47% from 2Q 2022). Profit margin: 9.0% (up from 7.2% in 2Q 2022). The increase in margin was driven by higher revenue. Reported Earnings • Aug 05
First quarter 2023 earnings released: EPS: ₹4.50 (vs ₹3.67 in 1Q 2022) First quarter 2023 results: EPS: ₹4.50 (up from ₹3.67 in 1Q 2022). Revenue: ₹1.23b (up 11% from 1Q 2022). Net income: ₹98.0m (up 47% from 1Q 2022). Profit margin: 8.0% (up from 6.0% in 1Q 2022). The increase in margin was driven by higher revenue. Board Change • Apr 27
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Non-Executive Independent Director Gaurav Gulati was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment improved over the past week After last week's 16% share price gain to ₹243, the stock trades at a trailing P/E ratio of 17.8x. Average trailing P/E is 36x in the Life Sciences industry in India. Reported Earnings • Feb 03
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹3.81 (down from ₹6.75 in 3Q 2021). Revenue: ₹1.19b (up 1.0% from 3Q 2021). Net income: ₹83.1m (down 32% from 3Q 2021). Profit margin: 7.0% (down from 10% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Reported Earnings • Sep 12
First quarter 2022 earnings released: EPS ₹3.67 (vs ₹0.25 in 1Q 2021) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹1.11b (up 50% from 1Q 2021). Net income: ₹66.9m (up ₹62.2m from 1Q 2021). Profit margin: 6.0% (up from 0.6% in 1Q 2021). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Sep 07
Investor sentiment improved over the past week After last week's 15% share price gain to ₹398, the stock trades at a trailing P/E ratio of 39.6x. Average trailing P/E is 45x in the Life Sciences industry in India. Board Change • Aug 17
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Non-Executive Independent Director Gaurav Gulati was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.